Sugi Predict

Sugi Predict / Compounds / SCHEMBL1663503

SCHEMBL1663503

SCHEMBL1663503

COc1ccc(COc2ccc3c(=O)n(-c4ccc(C#N)cc4)c(C(C)C)nc3c2C=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.50
▸ CXCR3 P49682 3/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ NPSR1 Q6W5P4 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ CSF1R P07333 2/20 0.37
▸ TSHR P16473 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ KIT P10721 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663651 0.87 TRPV1 (0.51) TRPV1CXCR3ALDH1A1NPSR1POLB
SCHEMBL1664000 0.87 TRPV1 (0.52) TRPV1CXCR3ALDH1A1NPSR1POLB
SCHEMBL1662486 0.80 TRPV1 (0.60) TRPV1CXCR3KCNH2HRH3
SCHEMBL10446401 0.72 TRPV1 (0.60) TRPV1CXCR3KCNH2HRH3
SCHEMBL1663563 0.72 TRPV1 (0.60) TRPV1CXCR3KCNH2HRH3
SCHEMBL12605087 0.70 TRPV1 (0.54) TRPV1CXCR3KCNH2HRH3
SCHEMBL10446284 0.70 TRPV1 (0.57) TRPV1CXCR3KCNH2HRH3
SCHEMBL10446186 0.69 TRPV1 (0.64) TRPV1CXCR3ALDH1A1KCNH2HRH3
SCHEMBL1663348 0.69 TRPV1 (0.60) TRPV1CXCR3KCNH2HRH3
SCHEMBL10446190 0.69 TRPV1 (0.60) TRPV1CXCR3KCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 — — EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 — — US disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 — — US disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 — — US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 — — EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 — — WO disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885CXCR3 312/4885ALDH1A1 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.